Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8152W HIGH $8.62
Volume
10.72 K
Value Traded
45.76 K
Short % Float
5.05%
Days to Cover
1.6
+5.28%Week
-30.32%1 Month
-44.52%3 Month
-46.23%6 Month
-99.84%5 Year
-99.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.06 M
EPS (TTM)
-2.31
P/E Ratio
-
Ent. Value
2.19 M
Total Shares
3.52 M
Float Shares
2.64 M
Insiders
24.84%
Institutions
13.51%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SXTP Catalyst Timeline
Dated clinical, regulatory and corporate events for 60 Degrees Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for 60 Degrees Pharmaceuticals, Inc.
125Total events
11Upcoming
34Tier-1 (high impact)
2023 to 2035Coverage
Upcoming catalysts 2
Event history 50
●Interim AnalysisTafenoquineApprovedTrial
DSMB interim analysis of tafenoquine severe babesiosis study completed
severe babesiosissource ↗
●DSMB ReviewTafenoquineApprovedTrial
DSMB recommended completing study with originally planned N=33 patients
severe babesiosissource ↗
●Enrollment UpdateTafenoquineApprovedTrial
30 patients enrolled in severe babesiosis study as of October 1, 2026
severe babesiosissource ↗
▲Enrollment MilestoneTafenoquineApprovedTrial
Minimum 24 patients enrolled to trigger interim analysis
babesiosissource ↗
▲Enrollment CompleteTafenoquineApprovedTrial
Minimum enrollment of 24 patients achieved in hospitalized babesiosis study
babesiosissource ↗
▲Partnership / LicensecastanospermineCorporate
Exclusive option agreement with Florida State University for castanospermine IP
Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, post-treatment Lyme diseasesource ↗
◆FDA Feedback ReceivedFDA Meeting
FDA meeting to discuss New Dietary Ingredient Notification for Australian Chestnut Extract
dietary supplementsource ↗
▲DSMB ReviewTafenoquineApprovedTrial
DSMB recommends continuation of B-FREE study after safety review of first six patients
chronic babesiosissource ↗
◆Type B MeetingFDA Meeting
FDA meeting to discuss Non-Notification Letter for NDIN
dietary supplementsource ↗
▲Partnership / LicenseCorporate
Exclusive patent license agreement with Florida State University for Australian Chestnut Extract
◆FDA Feedback ReceivedFDA Meeting
FDA issued Non-Notification Letter for NDIN of Australian Chestnut Extract
dietary supplementsource ↗
▲Partnership / LicenseARAKODAApprovedCorporate
Partnership with Runway Health to provide direct access to ARAKODA for international travelers
malaria preventionsource ↗
◆Timing GuidanceTafenoquineApprovedPresentation
Plan to file NDA for supplemental indication in babesiosis
babesiosissource ↗
▲Full ResultsTafenoquineApprovedClinical Data
All patients cured in expanded access study for relapsing babesiosis
relapsing babesiosissource ↗
▲Partnership / LicenseARAKODAApprovedCorporate
GoodRx partnership to offer savings on ARAKODA
malaria preventionsource ↗
▲Partnership / LicenseARAKODAApprovedCorporate
Partnered with GoodRx to provide savings on ARAKODA
malaria preventionsource ↗
▲Partnership / LicenseCorporate
Exercised option to negotiate exclusive license for large-scale purification of castanospermine from FSU
●Manufacturing MilestoneCMC / Inspection
Developed and tested prototype capsule formulations for oral delivery
◆Other Regulator MilestoneEx-US Regulatory
Ready to commence regulatory process for U.S. market access as botanical product for non-Rx use
▼Reverse Stock SplitCorporate
Reverse stock split at 1:4 ratio approved by board and filed with Delaware Secretary of State
◆Topline ReadoutTafenoquineApprovedClinical Data
Data expected from one or more babesiosis studies
babesiosissource ↗
◆Type B MeetingTafenoquineApprovedFDA Meeting
Company plans to request Type B meeting with FDA in early 2026
babesiosissource ↗
▲Partnership / LicenseARAKODAApprovedCorporate
Partnered with Runway Health to expand ARAKODA sales via telehealth
malaria preventionsource ↗
●Partnership / LicenseCorporate
Exercised Florida State University license option for large-scale purification of castanospermine
◆Topline ReadoutARAKODAApprovedClinical Data
Data expected from one or more babesiosis studies
babesiosissource ↗
▲PublicationPresentation
Detection of Babesia infection in 24% of chronic fatigue patients published in Pathogens
chronic fatigue associated with Babesia infectionsource ↗
◆Enrollment UpdateTafenoquineApprovedTrial
B-Free Study now enrolling at Icahn School of Medicine at Mount Sinai
chronic babesiosissource ↗
▼Breakthrough Therapy DesignationARAKODAApprovedDesignation
FDA declined Breakthrough Therapy Designation request for ARAKODA in babesiosis
babesiosissource ↗
▲Quarterly UpdateARAKODAApprovedCorporate
Encouraging results from 6-month commercial pilot showing increased product sales
malaria prophylaxissource ↗
▲Enrollment MilestoneARAKODAApprovedTrial
Central study site open for patient enrollment
chronic babesiosissource ↗
▲Trial InitiationTafenoquineApprovedTrial
Central study site at Mount Sinai opened for enrollment in Phase 2 B-FREE study
chronic babesiosissource ↗
▲Primary Endpoint MetTafenoquineApprovedClinical Data
First patient tests negative for babesiosis infection following treatment
relapsing babesiosissource ↗
▲Trial InitiationARAKODAApprovedTrial
B-FREE chronic babesiosis trial initiated
chronic babesiosissource ↗
▲Breakthrough Therapy DesignationTafenoquineApprovedDesignation
Breakthrough Therapy Application submitted to FDA for tafenoquine in babesiosis
babesiosissource ↗
▲Product LaunchARAKODAApprovedPost-Market
Commercial pilot for malaria indication to address barriers to use and increase awareness
malariasource ↗
●Enrollment UpdateARAKODAApprovedTrial
19 patients randomized in placebo-controlled trial
babesiosissource ↗
◆Enrollment MilestoneTafenoquineApprovedTrial
Minimum enrollment target for hospitalized babesiosis study before end of 2025 tick season
hospitalized babesiosissource ↗
◆Oral PresentationPresentation
Management presentation at H.C. Wainwright 27th Annual Global Investment Conference
▲Product LaunchARAKODAApprovedPost-Market
Commercial pilot for malaria indication to address barriers and increase awareness
malariasource ↗
▲Trial InitiationTafenoquineApprovedTrial
Phase II clinical trial agreement signed with Icahn School of Medicine at Mount Sinai as central site
chronic babesiosissource ↗
▲Partnership / LicenseTafenoquineApprovedCorporate
Sponsored research agreement with Tulane University to study tafenoquine against Borrelia and Bartonella in cell culture
Lyme disease and Bartonellasource ↗
Past FDA Catalysts and PDUFA Decisions
How SXTP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2018-08-08 | Arakoda (tafenoquine succinate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 79%
Micro Cap(rank 519 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ARAKODA |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tafenoquine Small moleculeNCT06207370 | Babesiosis | Phase 2 | RECRUITING | 33 | Jul 1, 2027 | ||||||
| Tafenoquine Small moleculeNCT06656351 | Chronic Babesiosis | Phase 2 | RECRUITING | 40 | Sep 1, 2027 | ||||||
| Tafenoquine Small moleculeMarketedNCT04533347 | COVID 19 Disease | Phase 2 | COMPLETED | 86 | Jun 30, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every SXTP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| tafenoquine Orphan | chronic babesiosis | 2025-12-29 | 24 percent of a cohort of 50 patientsRead More | 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC StateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| DOW GEOFFREY SDirector, Officer (President and CEO) | Buy | 7,350 24,131 held | $1.38 | 06/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SXTP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SXTP for Q2 2026. | ||||
SXTP Institutional Ownership Trends
SXTP Short Interest
Shares sold short, counted twice a month.
5.05%
Short % of Float
of tradable shares sold short
133.4K
Shares Sold Short
-38.3% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
82.8K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SXTP ranks across every disease it competes in
Competitive Position is a premium feature
See how SXTP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSXTP News
SXTP▼ -22.9%on this news· ran to -33% by day 3
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees Pharmaceuticals plans to conclude enrollment in its severe babesiosis study with 30 patients and will unblind the study in January 2027. The company aims to request a pre-sNDA meeting with the FDA to discuss the regulatory pathway for tafenoquine in treating this disease. No safety issues were reported during the study.
Read more →SXTP▼ -6%on this news· ran to -17% by day 3shared move
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
60 Degrees Pharmaceuticals will release interim analysis results for tafenoquine in severe babesiosis on October 6, 2026. The company will also host a Key Opinion Leader webinar featuring experts Dr. Peter Krause and Dr. Edouard Vannier to discuss the clinical data and the potential role of tafenoquine. This event highlights the urgent need for new therapies in treating babesiosis.
Read more →SXTP60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
60 Degrees Pharmaceuticals announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026. The company will provide a pre-recorded presentation on its programs targeting vector-borne diseases, available from September 11, 2026. Management will also hold one-on-one meetings with investors during the event.
Read more →SXTP60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharmaceuticals reported its financial results for Q2 2026, showing a significant increase in net product revenues by 106% compared to the previous year. However, the company also experienced a rise in net loss and operating expenses. The firm continues to focus on developing treatments for vector-borne diseases, with ongoing clinical trials for babesiosis.
Read more →SXTP▼ -16.1%on this news
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals, Inc. has entered into agreements for a private placement of 574,713 shares of common stock and associated warrants, priced at $1.74 per share. The offering is expected to raise around $1.0 million, which will be used for working capital. The closing is anticipated on or about July 31, 2026, pending customary conditions.
Read more →SXTP▼ -16.1%on this newsshared move
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
60 Degrees Pharmaceuticals has successfully enrolled the minimum required 24 patients for an interim analysis in its clinical study of tafenoquine for severe babesiosis. The interim data readout is expected by October 6, 2026, and the company plans to meet with the FDA to discuss the regulatory pathway for a New Drug Application. This study is crucial as there are currently no FDA-approved treatments for babesiosis.
Read more →SXTP60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharmaceuticals has signed an exclusive option agreement with Florida State University to develop castanospermine for various tick-borne diseases, including Powassan virus disease and Lyme disease. This agreement allows the company to negotiate a U.S. license for the patented technology and develop a commercialization strategy. The compound has shown broad antiviral activity in preclinical studies.
Read more →SXTP60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
60 Degrees Pharmaceuticals announced a positive recommendation from the Data Safety Monitoring Board to continue the B-FREE Phase 2 study of tafenoquine for treating chronic babesiosis patients suffering from severe fatigue. The study aims to assess the efficacy of tafenoquine in alleviating fatigue over a 90-day treatment period. Currently, there are no FDA-approved treatments for babesiosis, highlighting the significance of this research.
Read more →SXTP60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
60 Degrees Pharmaceuticals has signed an exclusive patent license with Florida State University to extract castanospermine from Australian Chestnut seeds for non-prescription use. The company plans to meet with the FDA on July 1, 2026, to discuss feedback on their New Dietary Ingredient Notification for the extract. The FDA's Non-Notification Letter raises questions about safety information required for market approval.
Read more →SXTP60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals has enrolled the first patient in a clinical trial evaluating tafenoquine for treating babesiosis. The trial is ahead of schedule, with a minimum enrollment expected by July 2026. This study aims to assess the drug's efficacy and safety in hospitalized patients, marking a significant step in addressing this tick-borne illness.
Read more →SXTP60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals reported its financial results for Q1 2026, showing a slight decline in net product revenues and an increase in operating expenses. The company achieved a gross profit of approximately $76,000, down from $90,000 in Q1 2025. Despite these challenges, 60 Degrees continues to focus on developing treatments for infectious diseases.
Read more →SXTP▼ -11.7%on this news· ran to -22% by day 1
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
60 Degrees Pharmaceuticals has announced that ARAKODA (tafenoquine), a malaria preventive, is now available for purchase on the Runway Health website. This FDA-approved medication offers a convenient once-weekly dosing option for travelers heading to malaria-endemic regions. The partnership with Runway Health allows patients to obtain prescriptions online, making malaria prevention more accessible.
Read more →SXTP▲ +15.9%on this news
60 Degrees Pharmaceuticals Announces 2025 Annual Results
60 Degrees Pharmaceuticals reported a 65% increase in net product revenues for FY 2025, reaching $1,005,000. The company also noted a reduction in operating expenses and an improvement in net loss compared to the previous year. Recent business highlights include successful treatment outcomes in an expanded access study and partnerships to enhance sales of its product ARAKODA. However, the company faces challenges such as high operating costs and inventory write-offs.
Read more →SXTP▼ -12.3%on this news
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
60 Degrees Pharmaceuticals has partnered with GoodRx to provide savings on ARAKODA, a malaria prevention medication. Starting February 2, 2026, eligible patients can access discounts of up to 30% at over 70,000 pharmacies nationwide. ARAKODA is the only FDA-approved, once-weekly prescription for malaria prophylaxis in the U.S.
Read more →SXTP▲ +7.9%on this news· ran to -24% by day 3shared move
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
60 Degrees Pharmaceuticals has exercised its option to negotiate an exclusive license with Florida State University for large-scale purification of castanospermine. This compound, derived from the seeds of Castanospermum australe, has shown potential in modulating carbohydrate metabolism and impacting disease outcomes in animal models. The company is now prepared to begin the regulatory process for U.S. market access for this botanical product.
Read more →SXTP▲ +152%on this newsshared move
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
60 Degrees Pharmaceuticals has partnered with Runway Health to improve access to ARAKODA, a malaria prevention drug, for international travelers. This initiative, starting April 2, 2026, will allow users to receive personalized medical treatment plans and medication delivery before their travels. ARAKODA is the only broad-spectrum, once-weekly prescription malaria prevention available in the U.S.
Read more →SXTP60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
60 Degrees Pharmaceuticals, Inc. has announced a one-for-four reverse stock split effective January 20, 2026. This decision aims to comply with Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares significantly, while the par value remains unchanged. Shareholders approved this move during a special meeting in October 2025.
Read more →SXTPDegrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. October 2025 1 - 8 - 26 Webinar Disclaimer and Forward - looking Statements 2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. DISCLAIM
Degrees Pharmaceuticals, Inc. has outlined a commercial strategy for its malaria treatment, ARAKODA. The plan includes increasing awareness and differentiating ARAKODA from generic alternatives through targeted marketing efforts. Additionally, the company aims to boost trial usage by engaging more inside sales representatives to prompt healthcare providers to prescribe the medication based on its unique attributes. They are also addressing affordability issues to manage the high out-of-pocket costs for patients, using tools like GoodRx discounts.
Read more →SXTP▼ -20.5%on this news
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
60 Degrees Pharmaceuticals announced that a study found Babesia infection in 24% of patients with chronic fatigue. This research, conducted at North Carolina State University, supports the theory that Babesia may prolong recovery from chronic fatigue. The company is currently enrolling participants in the B-Free Study to evaluate the efficacy of tafenoquine for treating chronic babesiosis.
Read more →SXTP▼ -7%on this news
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
60 Degrees Pharmaceuticals announced plans to expand sales and marketing for ARAKODA after a successful commercial pilot indicated increased demand. The company will enhance its digital marketing efforts and add clinical sites for babesiosis studies following FDA feedback. This expansion reflects the company's commitment to improving access to malaria prevention.
Read more →About 60 Degrees Pharmaceuticals, Inc.
Headquarters1025 CONNECTICUT AVENUE NW, WASHINGTON, DC, 20036
BIOPHARMAWATCH ELITE PLUS
Trade the next SXTP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime